| Literature DB >> 35883746 |
Melford Chuka Egbujor1, Maria Petrosino2, Karim Zuhra2, Luciano Saso3.
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling has become a key pathway for cellular regulation against oxidative stress and inflammation, and therefore an attractive therapeutic target. Several organosulfur compounds are reportedly activators of the Nrf2 pathway. Organosulfur compounds constitute an important class of therapeutic agents in medicinal chemistry due to their ability to participate in biosynthesis, metabolism, cellular functions, and protection of cells from oxidative damage. Sulfur has distinctive chemical properties such as a large number of oxidation states and versatility of reactions that promote fundamental biological reactions and redox biochemistry. The presence of sulfur is responsible for the peculiar features of organosulfur compounds which have been utilized against oxidative stress-mediated diseases. Nrf2 activation being a key therapeutic strategy for oxidative stress is closely tied to sulfur-based chemistry since the ability of compounds to react with sulfhydryl (-SH) groups is a common property of Nrf2 inducers. Although some individual organosulfur compounds have been reported as Nrf2 activators, there are no papers with a collective analysis of these Nrf2-activating organosulfur compounds which may help to broaden the knowledge of their therapeutic potentials and motivate further research. In line with this fact, for the first time, this review article provides collective and comprehensive information on Nrf2-activating organosulfur compounds and their therapeutic effects against oxidative stress, thereby enriching the chemical and pharmacological diversity of Nrf2 activators.Entities:
Keywords: Nrf2; anti-inflammation; antioxidant; organosulfur compounds
Year: 2022 PMID: 35883746 PMCID: PMC9311638 DOI: 10.3390/antiox11071255
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Domain organization of the transcription factor Nrf2. Nrf2 is characterized by seven highly conserved regions, Neh1 to Neh7. Neh1, Neh3, and Neh6 are located at the C-terminus of Nrf2, while Neh2, Neh4, and Neh5 are located in the N-terminal region. Neh1 contains a CNC-bZIP domain responsible for dimerization with small musculoaponeurotic fibrosarcoma (Maf) proteins and required for binding to ARE sequences in DNA. Neh2 domain controls the interaction with the cytoplasmic protein Keap1 via DLG and ETGE motifs. The Neh3 domain is required for the activation of transcription, along with the Neh4 and Neh5 domains that enhance Nrf2-mediated reporter gene transcription in an ATP-dependent manner. Neh4 and Neh5 domains are known as transactivation domains and are involved in the binding to the kinase-inducible domain interacting (KIX) and cysteine/histidine-rich domain 3 (CH3) domains of CBP (CREB (cAMP Responsive Element Binding protein)-binding protein). The Neh6 domain contains a serine-rich conserved region which is involved in degradation of Nrf2. This domain contains two binding sites (DSGIS and DSAPGS motifs) for the β-transducin repeat-containing protein (β-TrCP). Finally, the Neh7 domain interacts with the retinoic X receptor α, an Nrf2 repressor, and represses Nrf2 target gene transcription.
Figure 2(A) Regulation of Nrf2 activity by Keap1. (1.) Keap1 in dimeric form, complexed with Nrf2. (2.) Under basal conditions, Nrf2 interacts with Keap1 homodimer through ETGE and DLG motifs. This interaction allows the ubiquitination of Nrf2 at its Lys-rich (7K) region and the following proteasomal degradation of the protein by the 26S proteasome. (3.) The presence of Nrf2 activators (such as organosulfur compounds) promotes the release of Nrf2 thus leading to its nuclear translocation. Particularly, activators react with specific cysteine residues in Keap1 (Cys151, Cys273, or Cys288). In the nucleus, Nrf2 heterodimerizes with small Maf (sMaf) proteins and binds to the antioxidant response element (ARE), activating the expression of a battery of cytoprotective genes. (B) Structure of the Kelch domain of human Keap1 in complex with Nrf2 peptide (pdb #4IFL). The Kelch domain of Keap1 is characterized by a six-bladed β-propeller structure. Each blade, shown in a different color and numbered I–VI, is composed of four β-strands labeled A–D (as shown in white font on blade IV). The N and C termini are both located in blade I. The N and C termini of Nrf2 peptide are also indicated in figure. (C) Scheme of chemical Nrf2 activators including some organosulfur compounds. Four different classes of Nrf2 activators and representative chemicals for each class are reported. Class I contains the Cys151-preferring activators, class II the Cys288-preferring activators, class III the Cys151/Cys273/Cys288-preferring activators, and class IV the Cys151/Cys273/Cys288-independent activators.
Scheme 1Structure of sulfone.
Scheme 2Synthesis of sulfones.
Scheme 3Binding of Keap1 to Vinyl Sulfones.
Synthetic organosulfur compounds and their Nrf2 activation.
| Entry | Compounds | Effective Concentration/Dose | Biological Activity | Study Model | Targeted Diseases | Ref |
|---|---|---|---|---|---|---|
| 4 | 1–5 µM | Antioxidant, anti-inflammatory | Microglia, Parkinson’s disease animal model | Parkinson’s disease | [ | |
| 1–10 µM | Antioxidant, neuroprotection | MPTP-induced Parkinson’s disease mouse model | Parkinson’s disease | [ | ||
| 10 µM | Neuroprotection | HEK293 cells | Traumatic brain injury | [ | ||
| 5 | 10 µM | Antioxidant, neuroprotection | MPTP-induced Parkinson’s disease mouse model | Parkinson’s disease | [ | |
| 6 | 0.5–1 µM | Antioxidant, neuroprotection | PC12 Cells | Oxidative stress | [ | |
| 7 | 0.5–1 µM | Antioxidant, neuroprotection | PC12 Cells | Oxidative stress | [ | |
| 8 | 50–200 µM | Antioxidant | A549 Cells | Oxidative stress | [ | |
| 9 | 50–200 µM | Antioxidant | A549 Cells | Oxidative stress | [ | |
| 10 | 50–200 µM | Antioxidant | A549 Cells | Oxidative stress | [ | |
| 11 | 0.58 µM | Antioxidant, Keap1–Nrf2 PPI inhibition | RAW264.7 Cells | Inflammation | [ | |
| 12 | ≥500 µL | Antioxidant, Keap1–Nrf2 PPI inhibition | RAW264.7 Cells. HepG2 Cells, mice, rat | Inflammation | [ | |
| 13 | ≥500 µL | Antioxidant, Keap1–Nrf2 PPI inhibition | RAW264.7 Cells. HepG2 Cells, mice, rat | Inflammation | [ | |
| 14 | ≥500 µL | Antioxidant, Keap1–Nrf2 PPI inhibition | RAW264.7 Cells. HepG2 Cells, mice, rat | Inflammation, | [ | |
| 15 | 8.19 µM | Antioxidant, Keap1–Nrf2 PPI inhibition | RAW264.7 Cells | Inflammation | [ | |
| 16 | 10–100 µM | Keap1–Nrf2 PPI inhibition, Antioxidant, | Hepa1c1c7 mouse hepatic cells | Cytotoxicity | [ | |
| 17 | >10 µM | Antioxidant, anti-inflammatory, neuroprotection | MPTP-induced PD mouse model | Parkinson’s disease | [ | |
| 18 | 6.35 µM | Antioxidant, anti-inflammatory, neuroprotection | MPTP-induced PD mouse model | Parkinson’s disease | [ | |
| 19 | 0.076 µM | Antioxidant, anti-inflammatory, neuroprotection | MPTP-induced PD mouse model | Parkinson’s disease | [ | |
| 20 | 0.165 µM | Antioxidant, anti-inflammatory, neuroprotection | MPTP-induced PD mouse model | Parkinson’s disease | [ | |
| 21 | 0.237 µM | Antioxidant, anti-inflammatory, neuroprotection | MPTP-induced PD mouse model | Parkinson’s disease | [ | |
| 22 | 10 µg/mL | Antioxidant | RAW 264.7 Cells, MRC-5 Cells | Silicosis | [ | |
| 23 | 0.1–0.8% | Antioxidant, anti-inflammatory | Human umbilical vein endothelial cells (HUVECs) | Oxidative stress | [ | |
| 24 | 20 µM | Antioxidant, Nrf2 activation, HO-1 induction | BV-2 Cells | Parkinson’s disease | [ | |
| 25 | 20 µM | Antioxidant, Nrf2 activation, HO-1 induction | BV-2 Cells | Parkinson’s disease | [ | |
| 26 | 20 µM | Neuroprotection, Antioxidant | BV-2 Cells | Parkinson’s disease | [ | |
| 27 | 10 µM | Nrf2 activation, Antioxidant | HEK293 Cells | Traumatic brain injury (TBI) | [ | |
| 28 | 10 µM | Nrf2 activation, Antioxidant | HEK293 Cells | Traumatic brain injury (TBI) | [ | |
| 29 |
| 150 mg/kg | Antioxidant, Nrf2 activation | HepG2 cells and C57BL/6 mouse liver | oxidative stress | [ |
| 0.75 g/kg | Antioxidant | C57BL/6J mice | Obesity, insulin resistance, Oxidative stress | [ | ||
| 20 µM | Antioxidant | RSC96 cells | Oxidative stress, Apoptosis | [ | ||
| 12 µM | Antioxidant. Nrf2 activation | HEK293 cells | Kidney cell injury | [ | ||
| 500 mg/kg | Antioxidant, Chemoprevention | Mice | Cancer | [ | ||
| 250 mg/kg | Anticancer, Antioxidant | Mouse urothelial cells | Urinary bladder carcinogenesis | [ |
Scheme 4Synthesis of sulfonamides.
Figure 3Crystal structure of compound 14 in complex with human Keap1 Kelch domain (pdb #6UF0). Overall structure of Keap1 Kelch domain in complex with compound 14 and details of interaction (inset).
Scheme 5Sulfonate ion.
Scheme 6Synthesis of sulfonates.
Scheme 7Structure of sulfoxide.
Scheme 8Synthesis of dimethyl sulfoxide.
Scheme 9Synthesis of sulfoximine.
Natural organosulfur compounds and their Nrf2 activation.
| Entry | Compounds | Effective Concentration/Dose | Biological Activity | Study Model | Targeted Diseases | Ref |
|---|---|---|---|---|---|---|
| 30 | 0.4–100 µM | Antioxidant, anti-inflammatory | HepG2-C8 cells | Diabetic nephropathy, oxidative stress | [ | |
| 31 |
| 5 µM | Antioxidant | Mice | Hyperglycemia, oxidative stress | [ |
| 0.7 and 1.5 mg/kg | Antioxidant, anti-inflammatory | Rat | Gastric injury | [ | ||
| 32 |
| 10 mg/kg | Antioxidant, anti-inflammatory | C57BL/6J mice | Traumatic brain injury | [ |
| 40 µM | Antioxidant | 16HBE14o-cells | COPD | [ | ||
| 25 or 50 mg/kg | Hepatotoxicity, antioxidant | HepG2 and AML12 cells | Acetaminophen-induced liver injury | [ | ||
| 33 |
| 1–100 µM | Antioxiodant, cytoprotection | NIH3T3 cells | cytotoxicity | [ |
| 5 and 10 µM | Antioxidant, anti-inflammatory | C57BL/6J mouse strain | Inflammation | [ | ||
| 20 and 50 µM | Chemoprevention, antioxidant | HeLa cells | cancer | [ | ||
| 34 | 3–8 µM | Antioxidant | Human or rat epithelial cells | Oxidative stress | [ | |
| 110–440 µmol/kg | Anticancer, chemoprevention | Wild-type mice | Cancer | [ | ||
| 9 µmol/day | Anticancer, chemoprevention | Mice | Cancer | [ | ||
| 1–10 µM | Antioxidant, neuroprotection | PC12 Cells | Oxidative stress, apoptosis | [ | ||
| 35 | 5 µM | Anticancer, chemoprevention | RL34 Cells | Cancer | [ | |
| 36 | 21.50–43.00 mg, 100 g−1 body wt | Antioxidant | Growing rats | Oxidative stress | [ | |
| 21.2 mg/g | Antioxidant | Growing and adult rats | Oxidative stress | [ | ||
| 0.4–0.91% | Hepatic antioxidant | Lambs | Oxidative stress | [ | ||
| 37 | 10–80 mM | Antioxidant | Mouse spermatocytes (GC-2 Cells) | Oxidative stress | [ | |
| 2% | Antioxidant | Diabetic rats | Diabetic neuropathy | [ | ||
| 38 | 50 µMD/L | Antioxidant | Hepatoma cell line (HepG2 Cells) | Oxidative stress | [ | |
| 50 µM | Antioxidant | Hepatoma cell line (HepG2 Cells) | Oxidative stress | [ | ||
| 0–100 µM | Antioxidant | Hepatoma cell line (HepG2 Cells) | Oxidative stress | [ | ||
| 50 µM–1 mM | Antioxidant | Muller glial cells | Oxidative stress | [ | ||
| 39 | 600 mg | Antioxidant | Infertile men with asthenoteratozoospermia | Oxidative stress | [ | |
| 40 | 100 mg/kg | Antioxidant, neuroprotection | Mouse model of TBI | Oxidative stress, TBI | [ | |
| 41 | 10−4 M | Antioxidant, Cytoprotection | Bronchial epithelial cells (16-HBE) | Chronic obstructive pulmonary disease (COPD) | [ | |
| 42 | 70 mg/kg | Antioxidant, Anti-inflammatory | Rat | Nephrotoxicity | [ | |
| 125–500b nM | Antioxidant, Dermato-protection | Human keratinocytes | Skin damage, Oxidative stress | [ | ||
| 0.1–10 mM | Antioxidant, Anti-inflammatory | Human keratinocytes | Skin damage, Oxidative stress, Inflammation | [ | ||
| 43 |
| 10 µg/mL | Apoptosis | Colon cancer cells (HCT-116) | Colon cancer | [ |
| 40 µg/mL | Antioxidant, Anti-inflammatory | HUVECs | Oxidative stress, Inflammation | [ |